Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume – What’s Next?

Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-high trading volume on Thursday. 8,988 shares changed hands during mid-day trading, an increase of 172% from the average daily volume of 3,306 shares. The stock last traded at $12.3815 and had previously closed at $12.59.

Bavarian Nordic Stock Down 1.9%

The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of 12.17 and a beta of 1.25. The company’s 50 day moving average price is $11.31 and its 200 day moving average price is $10.13.

Bavarian Nordic (OTCMKTS:BVNRY) last released its earnings results on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. The firm had revenue of $316.47 million for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.

Bavarian Nordic Company Profile

Bavarian Nordic A/S is a Denmark-based biotechnology and vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. The company supplies products to government agencies, public-health organizations, healthcare providers and private-sector customers in markets around the world.

Its best-known product is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for travelers and other infectious-disease risks, including products targeting rabies, tick-borne encephalitis, typhoid and cholera, as well as selected pediatric and adult immunization needs.

Founded in 1994 and headquartered in Copenhagen, Bavarian Nordic has expanded from a vaccine research company into an international commercial vaccine manufacturer.